follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
new york -- busi -- pfizer inc nyse report financi result second-quart
rais financi guidanc adjust dilut ep
result second quarter first six month summar
februari complet sale global infus therapi net asset hospira infus system
therefor financi result first six month reflect contribut legaci
oper first six month reflect approxim one month legaci domest oper
approxim two month legaci intern oper
amount press releas may add due round percentag calcul use
unround amount refer oper varianc pertain period-over-period growth rate exclud
impact foreign exchang
pfizer updat financi guidanc present
revenu guidanc updat sole reflect recent unfavor chang foreign exchang rate relat
 dollar mid-april mid-juli primarili weaken euro chines yuan
guidanc adjust updat primarili reflect higher anticip spend second
half previous project larg relat late-stag develop program
guidanc adjust updat primarili reflect unreal net gain equiti
secur one-tim mileston payment certain collabor out-licens arrang gain
sale certain compound/product right first-half
guidanc effect tax rate adjust updat primarili reflect pfizer evolv
understand impact tax cut job act busi although estim
continu subject analysi interpret clarif tcja current expect
tax rate guidanc sustain beyond
financi guidanc adjust dilut reflect share repurchas total approxim billion alreadi
complet dilut relat share-bas employe compens program expect off-set
approxim half reduct share associ share repurchas
first six month return billion directli sharehold combin
billion dividend compos per share common stock first second
quarter
billion share repurchas compos billion open-market share repurchas first-quart
billion acceler share repurchas agreement execut march
juli remain share repurchas author billion
second-quart revenu total billion increas million compar prior-year
quarter reflect favor impact foreign exchang million oper growth
million
ih revenu increas oper second-quart primarili driven continu growth key
brand includ eliqui ibranc xeljanz global prevnar primarili emerg market
 well xtandi oper revenu growth eliqui ibranc xeljanz xtandi
respect
second-quart ih oper revenu growth neg impact primarili loss exclus
viagra decemb result shift report viagra revenu
canada essenti health busi begin ih oper revenu growth also
neg impact lower revenu enbrel develop europ market due continu biosimilar
global prevnar revenu increas oper second-quart
prevenar revenu intern market increas oper primarili due overal favor
impact time associ govern purchas pediatr indic certain emerg market
compar prior-year quarter well launch pediatr indic china second quarter
 prevnar revenu increas primarili due higher govern purchas second-quart
compar second-quart pediatr indic partial off-set continu declin
revenu adult indic due smaller remain catch opportun compar prior-year
second-quart eh revenu declin oper neg impact primarili
oper declin legaci establish product portfolio develop market
oper declin steril inject pharmaceut portfolio develop market primarili due
continu legaci hospira product shortag
oper declin peri-lo product portfolio develop market primarili due expect
declin lyrica develop europ partial off-set addit viagra revenu
canada previous record ih busi
partial off-set
oper growth emerg market reflect growth across portfolio
oper growth biosimilar primarili inflectra certain channel well
record higher insecond-quart compar prior-year quarter primarili
due
unreal net gain equiti secur primarili gain share inc stock held
receiv part consider sale net asset record unreal net
gain equiti secur reflect adopt new account standard first-quart prior
adopt new standard net unreal gain loss virtual equiti secur readili
determin fair valu report accumul comprehens incom
higher incom collabor out-licens arrang sale compound/product right
lower charg certain legal matter primarili reflect revers legal accrual second-quart
loss longer deem probabl
pfizer effect tax rate report second-quart favor impact decemb
enact
pfizer effect tax rate adjust second-quart favor impact
aforement decemb enact
second-quart dilut weighted-averag share outstand use calcul
dilut ep declin million share compar prior-year quarter primarili due on-going share
repurchas program reflect impact share repurchas first-quart partial off-set dilut
relat share-bas employe compens program
bavencio avelumab talazoparib -- juli first patient enrol phase javelin ovarian
parp trial evalu avelumab combin talazoparib patient previous untreat advanc
ovarian cancer javelin ovarian parp open-label intern multi-cent random studi design
evalu efficaci safeti avelumab combin chemotherapi follow mainten therapi
avelumab combin talazoparib treatment nave patient local advanc metastat ovarian
cancer stage stage iv trial explor potenti novel combin avelumab
develop part allianc merck kgaa darmstadt germani
ibranc palbociclib -- june announc receipt overal surviv os result phase
trial evalu ibranc combin fulvestr compar placebo plu fulvestr
women hormon receptor-posit hr human epiderm growth factor receptor
metastat breast cancer whose diseas progress prior endocrin therapi result demonstr
posit trend hazard ratio favor ibranc combin although trend reach statist
signific os secondari endpoint trial trial design optim
detect statist signific differ os expect present detail os data upcom
lyrica pregabalin -- may announc posit top-lin result phase studi examin use
lyrica oral solut cv adjunct therapi partial onset seizur pediatr epilepsi patient one month
less four year age result show adjunct treatment lyrica mg/kg/day result
statist signific reduct seizur frequenc versu placebo primari efficaci endpoint treatment
lyrica lower dose mg/kg/day result statist signific reduct seizur frequenc
versu placebo studi post-market requir food drug administr fda
lyrica approv adjunct therapi partial onset seizur pediatr epilepsi patient one month
less four year age complet studi result expect submit public peer-review
medic journal fda pediatr exclus determin
nivestym filgrastim-aafi -- juli announc fda approv nivestym biosimilar
filgrastim elig indic refer product
announc result studi analyz real-world effect data found prevnar
reduc risk hospit vaccine-typ pneumococc community-acquir pneumonia
ci adult age older importantli prevnar work real-world condit
peopl receiv pneumococc vaccin advis health care provid mani underli
medic condit increas risk pneumococc pneumonia result publish clinic
retacrit epoetin alfa-epbx -- may announc fda approv retacrit biosimilar
epogen procrit epoetin indic refer product enter
agreement vifor pharma inc commerci retacrit certain channel
vyndaqel tafamidi -- may announc fda grant breakthrough therapi design
tafamidi treatment patient transthyretin cardiomyopathi ttr-cm rare fatal
underdiagnos condit associ progress heart failur decis support top-line result
phase ttr-cm studi attr-act tafamidi demonstr statist signific reduct
combin all-caus mortal frequenc cardiovascular-rel hospit current
approv pharmacolog treatment specif indic diseas averag life expect
peopl ttr-cm year diagnosi fda breakthrough therapi design intend
expedit develop review medicin intend treat seriou life-threaten diseas
preliminari clinic evid indic drug may demonstr substanti improv exist
therapi expect result phase attr-act trial present late-break european
societi cardiolog congress munich germani august
xalkori crizotinib -- may announc fda grant breakthrough therapi design
xalkori treatment patient metastat non-smal cell lung cancer nsclc exon
alter diseas progress platinum-bas chemotherapi fda also grant
breakthrough therapi design xalkori treatment patient relaps refractori system
anaplast larg cell lymphoma anaplast lymphoma kinas -posit
june announc european commiss ec approv xeljanz mg twice daili bid
combin methotrex treatment activ psoriat arthriti adult patient
inadequ respons intoler prior disease-modifi antirheumat drug therapi
evalu efficaci safeti xeljanz mg bid compar placebo adult patient activ ankylos
spondyl studi conduct adult patient inadequ respons
intoler nonsteroid anti-inflammatori drug therapi xeljanz approv treatment
market
may committe medicin product human use chmp european medicin agenc
ema adopt posit opinion recommend market author xeljanz treatment adult
patient moder sever activ ulcer coliti uc chmp opinion review
ec author approv medic european union eu
may announc fda approv xeljanz mg bid least eight week follow
xeljanz mg bid mg bid treatment adult patient moder sever activ
xtandi enzalutamid -- juli astella pharma inc astella announc fda approv
supplement new drug applic xtandi fda action broaden indic xtandi men
castration-resist prostat cancer includ men non-metastat approv make
xtandi first oral medic fda-approv non-metastat metastat
comprehens updat develop pipelin publish today avail
www pfizer com/science/drug-product-pipelin includ overview research list compound
develop target indic phase develop well mechan action candid
phase candid phase registr
dacomitinib -- june announc os data archer trial evalu
dacomitinib first-lin treatment patient local advanc metastat nsclc egfr-activ
mutat compar gefitinib trial show median os month patient receiv dacomitinib
ci repres seven-month improv compar month gefitinib
ci os data archer present oral present annual
meet american societi clinic oncolog publish simultan journal clinic
juli spark announc initi phase open-label multi-
center lead-in studi evalu efficaci safeti current factor ix prophylaxi replac therapi
usual care set factor ix prophylaxi efficaci data obtain lead-in studi serv within-
subject control group patient enrol next part phase studi evalu
investig gene therapi fidanacogen elaparvovec treatment hemophilia phase program
initi follow recent transfer respons spark hemophilia gene therapi program
fidanacogen elaparvovec novel investig vector contain bio-engin adeno-
associ viru capsid high-act human coagul factor ix gene enabl patient produc factor
ix rather regularli inject factor ix
may spark announc cumul follow-up patient year
observ week particip on-going phase clinic trial investig
sever moder sever percent hemophilia discontinu routin infus factor ix
concentr annual bleed rate particip reduc annual infus rate
reduc none particip experienc seriou advers event
thrombot event factor ix inhibitor may data cutoff full result studi present
world feder hemophilia world congress may
glasdegib -- june announc fda accept compani new drug
applic nda grant prioriti review statu glasdegib investig oral smoothen inhibitor
evalu treatment adult patient previous untreat acut myeloid leukemia combin
low-dos cytarabin type chemotherapi prescript drug user fee act pdufa goal date
decis fda decemb fda grant prioriti review medicin may offer signific
advanc treatment may provid treatment adequ therapi exist
lorlatinib -- juli fda notifi review period nda lorlatinib
extend three month allow time review addit inform recent submit
respons fda inform request submiss addit inform determin fda
constitut major amend nda result extens pdufa goal date three month
august novemb fda previous grant prioriti review statu lorlatinib nda
februari lorlatinib investig next-gener tyrosin kinas inhibitor
regulatori review treatment patient alk-posit metastat nsclc previous treat one
inhibitor
-- second-quart achiev proof-of-concept next-
gener multi-val pneumococc conjug vaccin candid result recently-complet phase
trial demonstr vaccin candid safe well-toler induc function immun
respons could kill twenti serotyp develop potenti extend coverag
beyond thirteen serotyp cover prevnar includ seven addit serotyp preval caus
pneumococc diseas adult children current plan phase program
rivipansel -- juli updat estim complet date rivipansel evalu
safeti efficaci time discharg reset phase trial investig canada continu
enrol sickl cell diseas scd patient studi complet expect second quarter
studi previous expect complet late updat calcul base histor
enrol last month rivipansel studi treatment vaso-occlus crisi
hospit subject scd
talazoparib -- june announc fda accept file grant prioriti
review statu compani nda talazoparib investig once-daili oral poli ribos
polymeras parp inhibitor treatment germlin inherit brca-mut local advanc
metastat breast cancer pdufa goal date decis fda decemb ema also
accept market author applic talazoparib patient popul
tanezumab -- juli compani lilli announc
week phase studi patient osteoarthr oa pain evalu subcutan administr tanezumab
investig human monoclon antibodi met three co-primari endpoint studi demonstr
patient receiv two dose tanezumab separ eight week experienc statist signific
improv pain physic function patient overal assess oa compar
receiv placebo preliminari safeti data show tanezumab gener well toler approxim
patient discontinu treatment due advers event rapidli progress oa observ
tanezumab-tr patient frequenc less observ placebo arm
event osteonecrosi observ trial new safeti signal identifi tanezumab part
investig class pain medic known nerv growth factor inhibitor addit oa pain
evalu chronic low back pain cancer pain due bone metastas lilli expect
present detail efficaci safeti data tanezumab upcom medic meet
trazimera biosimilar trastuzumab -- juli announc european commiss approv
trazimera biosimilar treatment overexpress breast cancer
overexpress metastat gastric gastroesophag junction adenocarcinoma approv follow
recommend chmp may
juli announc increas commit manufactur million
invest build one technic advanc steril inject pharmaceut product facil
world portag michigan invest strengthen capabl produc suppli
critic life-sav inject medicin patient around world known modular asept process
new multi-stori product facil also support area economi creat
estim new job next sever year expand presenc portag locat
kalamazoo counti compani employ peopl one largest plant
juli announc organ compani three busi includ
science-bas innov medicin busi includ current innov health busi
unit except consum healthcar well biosimilar new hospit medicin busi unit
commerci pfizer global portfolio steril inject anti-infect medicin
off-pat brand gener establish medicin busi oper substanti autonomi within
expect
consum healthcar busi continu evalu strateg altern decis
chang effect begin compani fiscal year provid financi
report reflect reorgan begin issuanc first-quart earn
june fda inform complet evalu correct action close
februari warn letter issu mcpherson kansa manufactur facil determin
address violat contain warn letter futur fda inspect regulatori
activ assess adequaci sustain correct site remain voluntari
june announc plan invest million biotechnolog emerg growth
compani pfizer ventur compani ventur invest vehicl addit increas fund
extend leadership ventur capit investor expand team leverag expertis
across ventur capit invest busi develop drug discoveri clinic develop
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
cousin charl pfizer charl erhart found charl pfizer compani red brick build
brooklyn ny one world largest pharmaceut compani list new york stock
exchang share compon jone industri averag sinc leader
american chemic busi mark anniversari portfolio includ wide array industri
pharmacolog product anchor citric acid camphor cream tartar borax iodin compani
offic new york chicago contact import-export busi crisscross world
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
januari found global biopharmaceut compani focu capabl
address world greatest health challeng stabil resourc expertis passion
discov develop bring market groundbreak scienc solv biggest health problem face
world today tomorrow
one world lead biotechnolog compani values-bas compani deepli root
scienc innov transform new idea discoveri medicin patient seriou ill
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
baxter touch million live everi day product servic essenti build block healthcar
youll find baxter product therapi nearli everi floor everi depart almost everi hospit
world-wide youll find us clinic home
bristol-my squibb global biopharma compani firmli focus mission discov develop deliv
innov medicin help patient prevail seriou diseas bristol-my squibb uk aim deliv
commit patient custom employe commun environ
 compani found colonel eli lilli man commit creat high-qual medicin
meet real need centuri later passion build preced continu
pursuit make life better individu commun world around us
found year ago genentech lead biotechnolog compani discov develop
manufactur commerci medicin treat patient seriou life-threaten medic condit
compani member roch group headquart south san francisco california
johnson johnson famili compani engag research develop manufactur
sale broad rang product health care field virtual countri world johnson johnson
primari interest histor current product relat human health well-b
johnson johnson incorpor state new jersey
base unit state distribut health care system medic suppli pharmaceut
product also provid specialti pharmaceut solut biotech pharmaceut manufactur well
practic manag technolog clinic support oncolog specialti practic addit
deliv comprehens offer healthcar product technolog equip relat servic non-
hospit market includ physician offic surgeri center long-term care facil home healthcar
merck compani inc american pharmaceut compani one largest pharmaceut compani
world compani establish unit state subsidiari german compani merck
found merck famili global healthcar compani histori work
make differ compani known merck unit state canada everywher els known
msd base kenilworth oper countri
novarti intern ag swiss multi-national pharmaceut compani base basel switzerland novarti
creat merger ciba-geigi sandoz novarti predecessor compani trace
root back year rich histori develop innov product novarti manufactur
lamisil other
novo nordisk global healthcar compani year innov leadership diabet care
compani aim provid medic treat wide rang diseas obes haemophilia growth
disord seriou chronic diseas base denmark novo nordisk employ approxim
peopl countri market product countri
open first manufactur facil michigan sign first larg private-label
custom pave way convers re-packag home remedi manufactur
afford health care product shift strateg direct drove growth next sever
decad becam foundat compani mission today perrigo world largest manufactur
over-the-counter healthcar product supplier infant formula store brand market compani also lead
provid brand over-the-counter product throughout europ well lead produc extend
topic prescript drug headquart ireland sell product primarili north america
europ well market includ australia israel china
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
sanofi french multi-national pharmaceut compani headquart pari franc world
fifth-largest prescript sale sanofi employe repres nation
oncolog thrombosi vaccin world largest produc latter subsidiari sanofi
teva establish global headquart base israel today portfolio
molecul produc approxim billion tablet capsul year manufactur facil
rank among lead pharmaceut compani world activ countri approxim
employe around world dedic mission
found california icn pharmaceut valeant grew rapidli seri merger
acquisit leadership michael pearson short period time valuabl
compani canada largest acquisit bausch lomb salix pharmaceut
manufactur market broad rang brand gener pharmaceut over-the-count over-the-counter product
medic devic contact lens intraocular lens ophthalm surgic equip aesthet devic
directli indirectli countri region includ unit state canada europ
east africa asia pacif latin america
unit state us popul million peopl embodi one complex health care
system world intertwin relationship provid payer patient receiv care
histor day us health care system constant state evolut trail behind china
india us third popul countri world spend trillion health care
gross domest product switzerland unit kingdom spent
respect health care growth health care spend mostli attribut growth
pharmaceut drug devic sinc attribut growth per year
depart human servic hh feder level primari agenc respons
regul health care system us state certain degre self-govern also
depart doh implement state-level health polici care provis financ
serv formerli serv militari independ manag either depart defens dod
depart veteran affair va two depart financ total health expenditur
health care sector multi-pay system compos public privat financ sourc public health
insur scheme oper center medicar medicaid servic medicar medicaid
children health insur program chip financ primarili govern tax medicar largest
singl payer us provid health care coverag age year older -- regardless incom
medic histori -- age perman disabl end-stag renal diseas medicaid
jointli fund feder govern individu state state set guidelin regard
elig servic reimburs medicaid provid care individu poverti level
afford pay health care given elig chip nation health insur program children
year age elig insur plan includ privat insur coverag
privat financ sourc consist privat health insur plan out-of-pocket payment individu
insur via public privat plan sever nation health insur plan well region
self-insur plan organ larg compani us common employ contribut privat
insur premium either whole part employe individu also buy privat health insur
privat insur collect premium individu employ turn pay
provid hospit physician health servic accord contract provid
individu neither cover public health insur scheme privat health plan pay out-of pocket
point servic moreov individu health insur respons pay co-pay insur
provid complet coverag total out-of-pocket spend billion out-of-pocket
cost insur patient retail medicin alon billion
public privat hospit except special veteran facil receiv payment
public privat financ sourc hospit typic paid base diagnost relat group drg
payment drg wide use mani privat payer payment scheme hospit drg-
base payment cover accommod cost hospit room board facil cost etc procedur cost
support staff nurs technician etc drug/med devic cost howev system includ
physician fee drug reimburs inpati drg though especi expens
innov drug paid separ outpati drg call ambulatori payment classif apc
drg payment rate updat per year base standard payment drg region wage
differ region cost live differ type health care provid taken account
calcul final payment procedur use variou index inform drg payment
found websit
privat insur pay hospit basi drg case rate per-diem fee-for-servic discount fee-for-
servic scheme averag payment exceed hospit cost provid underli servic
theori margin built payment cover loss hospit may serv uninsur
care servic provid commun hospital-bas health care profession solo-pract self-
employ gener practition physician may employ hospit medic group either privat
affili hospit typic locat within larg teach hospit increas number primari care
practic purchas hospit physician becom hospit employe ambulatori
secondari tertiari care provid hospital-bas doctor either self- hospital-employ
nation hospit mix public privat though privat hospit mostli not-for profit domin
number public hospit typic large-s tertiari teach hospit
individu may choos health care provid base coverag particular health insur plan
exampl health mainten organ hmo plan provid health insur health care servic
enrolle howev individu restrict health care servic provid avail within
hmo network similarli prefer provid organ ppo plan contract specif health care provid
restrict access contract physician enrolle ppo insur option treat
non-contract provid would need pay significantli out-of-pocket sinc provid consid out-
physician self-employ paid fee-for-servic patient cover public
health insur scheme medicar medicaid chip price health care servic defin
base either physician fee schedul medicaid price procedur conduct
physician calcul base nation uniform rel valu unit rvu point given
procedur region cost per unit privat insur also pay self-employ physician base
physician fee schedul howev differ rate negoti physician privat insur
us health care system reli heavili privat sector character lack univers health
care insur case differ develop countri patient protect afford act hr
sign law march allow greater access health care particularli among
uninsur bill phase sever year aim chang us health care system system
almost univers access health insur start octob open enrol began health insur
market place full summari afford act found henri kaiser famili
new law make mandatori employ employ fulltim employe provid health
insur coverag full-tim employe otherwis face financi penalti likewis citizen except
low incom expect enrol form health insur els face penalti law
expand elig medicaid allow peopl insur could afford insur
previous abl buy tax-pay subsid coverag diagram health coverag afford
act kaiser famili foundat identifi options/avail health care coverag addit new
law make illeg insur compani refus coverag peopl pre-exist medic condit
stop coverag becom ill
intern societi pharmacoeconom outcom researh
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
